BMY Stock Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 3/6 |
Dividends | 5/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Warren
Based on Analyst Price Targets
Price at publication US$52.49
Updated
Bristol-Myers Squibb Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$51.59 |
52 Week High | US$71.07 |
52 Week Low | US$47.58 |
Beta | 0.37 |
1 Month Change | 3.47% |
3 Month Change | -1.00% |
1 Year Change | -23.27% |
3 Year Change | -18.60% |
5 Year Change | 8.63% |
Change since IPO | 2,314.45% |
Recent News & Updates
Recent updates
Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield
Mar 07Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60
Mar 07We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative
Feb 20Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Feb 06Bristol-Myers Squibb: Massive Discount Spells Opportunity
Feb 04BMY: Might Be Approaching A Bottom In 2024
Jan 23Investors Aren't Entirely Convinced By Bristol-Myers Squibb Company's (NYSE:BMY) Earnings
Jan 16Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also
Jan 10Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
Dec 31Bristol-Myers Squibb (NYSE:BMY) Has Announced That It Will Be Increasing Its Dividend To $0.60
Dec 26Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now
Dec 19Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock
Dec 12Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.60
Dec 11Bristol-Myers Squibb: The Patent Expiry Challenge
Nov 23Bristol Myers Squibb: Bright Future Ahead
Nov 17Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet
Nov 08Bristol-Myers Squibb: Time To Get Greedy
Oct 21Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud
Oct 09Bristol Myers Squibb: Close To Fair Value, Headwinds For Next Few Years
Sep 26Shareholder Returns
BMY | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -5.1% | -0.3% | 0.5% |
1Y | -23.3% | 22.4% | 29.0% |
Return vs Industry: BMY underperformed the US Pharmaceuticals industry which returned 22.5% over the past year.
Return vs Market: BMY underperformed the US Market which returned 28.4% over the past year.
Price Volatility
BMY volatility | |
---|---|
BMY Average Weekly Movement | 2.8% |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BMY has not had significant price volatility in the past 3 months.
Volatility Over Time: BMY's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1887 | 34,100 | Chris Boerner | https://www.bms.com |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Bristol-Myers Squibb Company Fundamentals Summary
BMY fundamental statistics | |
---|---|
Market cap | US$105.84b |
Earnings (TTM) | US$8.03b |
Revenue (TTM) | US$45.01b |
13.0x
P/E Ratio2.3x
P/S RatioIs BMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BMY income statement (TTM) | |
---|---|
Revenue | US$45.01b |
Cost of Revenue | US$10.52b |
Gross Profit | US$34.49b |
Other Expenses | US$26.46b |
Earnings | US$8.03b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
Earnings per share (EPS) | 3.97 |
Gross Margin | 76.63% |
Net Profit Margin | 17.83% |
Debt/Equity Ratio | 135.1% |
How did BMY perform over the long term?
See historical performance and comparisonDividends
4.7%
Current Dividend Yield60%
Payout RatioDoes BMY pay a reliable dividends?
See BMY dividend history and benchmarksBristol-Myers Squibb dividend dates | |
---|---|
Ex Dividend Date | Apr 04 2024 |
Dividend Pay Date | May 01 2024 |
Days until Ex dividend | 16 days |
Days until Dividend pay date | 43 days |
Does BMY pay a reliable dividends?
See BMY dividend history and benchmarks